The Silent Pandemic: Tackling Antimicrobial Drug Resistance (AMR)

3:00 PM - 4:00 PM (PDT), Wednesday, June 15, 2022


Modern medicine as we know it is threatened by antimicrobial resistance (AMR). From common surgeries to cancer treatments, drug-resistant pathogens are on track to undermine decades of medical advances and cause once treatable common infections and routine surgeries to be fatal – in fact infectious diseases are already the second leading cause of death for patients with cancer. Although clinicians, health policy professionals, governments, our industry and the public have recognized the rise of AMR as a growing threat, significant challenges remain in bringing innovative new drugs to patients. Hear from a panel of industry leaders, investors, and government representatives about the challenges in innovation for AMR, the ties between antimicrobials and pandemic preparedness, and policy solutions under consideration today to address the fragile ecosystem for this critical segment of medicine.  


Founder President
President & CEO
The Medicines Company San Diego LLC - c/o Qpex Biopharma
Director of COVID Vaccine Development
Department of Defense Countermeasures Acceleration Group
AMR Action Fund